



DOCKET NO.: M0656.70071US00


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Vernon M. Ingram et al.
Serial No.: 10/051,663
Confirmation No.: 3098
Filed: January 18, 2002
For: TREATMENT FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE

Examiner: Celsa, Bennett M.
Art Unit: 1639

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 20 day of December, 2004.


June Watson

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. §1.114.

No fee or certification is required.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby makes the following additional information of record in the above-identified application.

The Applicant would like to bring to the Examiner's attention the following co-pending applications that may contain subject matter related to this application:

| <u>Docket No.</u> | <u>Serial No.</u> | <u>Filing Date</u> | <u>Inventor(s)</u> |
|-------------------|-------------------|--------------------|--------------------|
| M0656.70060US00 | 09/706,574 | November 3, 2000 | Ingram et al. |

The Applicant would like to bring to the Examiner's attention the enclosed search report from a corresponding International or Foreign National Application.

| <u>Docket No.</u> | <u>Serial No.</u> | <u>Mailing Date</u> | <u>Type of Communication</u> |
|-------------------|-------------------|---------------------|------------------------------|
| M0656.70027EP00 | 98902522.6 | July 13, 2004 | Official Communication |

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

Serial No.: 10/051,663
Conf. No.: 3098

- 3 -

Art Unit: 1639

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.


By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.


Notwithstanding any statements by the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,
Vernon M. Ingram et al., Applicant

By: 
John R. Van Amsterdam, Reg. No. 40,212
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
Telephone: (617) 646-8000

Docket No.: M0656.70071US00
Date: December 15, 2004
xNDDx



FORM PTO-1449/A and B (Modified)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

APPLICATION NO.: 10/051,663

DOCKET NO.: M0656.70071US00

FILING DATE: January 18, 2002

CONFIRMATION NO.: 3098

APPLICANT: Vernon M. Ingram et al.

GROUP ART UNIT: 1639

EXAMINER: Celsa, Bennett M.

Sheet

1

of

1

U.S. PATENT DOCUMENTS

| Examiner's Initials | Cite No. | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication or of issue of Cited Document MM-DD-YYYY |
|------------------------|-------------|----------------------|--------------|--|--|
| | | Number | Kind Code | | |
| | A27 | 2003-0105152 | A1 | Ingram, et al. | 06-05-2003 |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner's Initials | Cite No. | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document (not necessary) | Date of Publication of Cited Document MM-DD-YYYY | Translation (Y/N) |
|------------------------|-------------|-------------------------|----------|--------------|---|---|----------------------|
| | | Office/ Country | Number | Kind Code | | | |
| | B3 | WO | 96/37212 | A1 | Blondelle et al. | 11-28-1996 | |
| | B4 | WO | 98/08868 | A1 | Praecis Pharmaceutical Incorporated | 03-05-1998 | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

OTHER ART — NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No | Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published. | Translation (Y/N) |
|------------------------|------------|---|----------------------|
| | C29 | TJERNBERG et al., Arrest of beta-amyloid fibril formation by a pentapeptide ligand. J Biol Chem. 1996 Apr 12;271(15):8545-8. | |
| | C30 | TJERNBERG et al., Controlling amyloid beta-peptide fibril formation with protease-stable ligands. J Biol Chem. 1997 May 9;272(19):12601-5. | |
| | | | |

EXAMINER:

DATE CONSIDERED:

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an eIDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]